Cell Therapy DA01 Cleared for Phase 1 Trial in Advanced Disease Patients

Cell Therapy DA01 Cleared for Phase 1 Trial in Advanced Disease Patients

282378

Cell Therapy DA01 Cleared for Phase 1 Trial in Advanced Disease Patients

The U.S. Food and Drug Administration (FDA) has cleared a request to open a Phase 1 clinical trial of DA01, an investigational cell therapy aiming to restore neurons lost to Parkinson’s, in people with advanced disease. “Today, there is no disease-modifying treatment for Parkinson’s. Through this trial and those to follow, we hope to change that,” Emile Nuwaysir, PhD, president and CEO of BlueRock Therapeutics, said in a press release. Developed by BlueRock, a wholly…

You must be logged in to read/download the full post.